Ascendis Pharma A/S (ASND) Expected to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.29 per share and revenue of $430.2140 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. On average, analysts expect Ascendis Pharma A/S to post $4 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Down 0.9%

Shares of Ascendis Pharma A/S stock opened at $252.05 on Thursday. Ascendis Pharma A/S has a 1 year low of $163.88 and a 1 year high of $282.15. The company has a market cap of $15.72 billion, a P/E ratio of 29.07 and a beta of 0.37. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The stock has a 50-day moving average price of $244.94 and a 200 day moving average price of $234.50.

Analyst Upgrades and Downgrades

ASND has been the topic of a number of research reports. Evercore reiterated an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a report on Friday, May 15th. Wells Fargo & Company lowered their price objective on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada increased their target price on shares of Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, Barclays boosted their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average price target of $296.72.

Insider Activity

In related news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jean Jacques Bienaime acquired 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the acquisition, the director directly owned 400 shares of the company’s stock, valued at $95,120. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of ASND. Aigen Investment Management LP acquired a new position in Ascendis Pharma A/S during the fourth quarter worth $252,000. Commonwealth Equity Services LLC bought a new position in Ascendis Pharma A/S during the fourth quarter valued at about $249,000. Rhumbline Advisers lifted its position in shares of Ascendis Pharma A/S by 4.0% in the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares during the last quarter. PharVision Advisers LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth about $233,000. Finally, Graham Capital Management L.P. bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth about $228,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.